CYBB Gene Genetic Test for X-Linked Chronic Granulomatous Disease | Dubai, UAE | DNA Labs UAE

Executive Summary & Core Metrics

Executive Summary: DNA Labs UAE offers a definitive diagnostic genetic test for X-linked chronic granulomatous disease (CGD) via next-generation sequencing (NGS) of the CYBB gene. This advanced genomic analysis delivers a diagnostic sensitivity of 99.9% for pathogenic variants, including point mutations, small insertions/deletions, and large copy number variations (CNVs). The test is performed at our ISO 9001:2015 accredited facility (Certificate: INT/EGQ/2509DA/3139) in Dubai Healthcare City. With a turnaround time of 3-4 weeks, the service includes secure online result delivery and a mandatory telephonic post-test consultation. The test price is 2,800 AED. For insurance coverage inquiries, contact our team via WhatsApp at +971 54 548 8731.

Test Overview & Methodology

The CYBB gene NGS test is a comprehensive molecular analysis designed to identify disease-causing mutations in the CYBB gene, which encodes the gp91phox subunit of the NADPH oxidase complex. Pathogenic variants in this gene lead to X-linked chronic granulomatous disease, a severe primary immunodeficiency characterized by recurrent, life-threatening bacterial and fungal infections, granuloma formation, and impaired neutrophil function. This NGS-based approach provides superior diagnostic accuracy compared to traditional Sanger sequencing by detecting all mutation types across the entire coding region and splice sites, including large deletions and duplications that Sanger methods may miss. The test is a critical tool for diagnosing affected males, identifying female carriers, and guiding treatment strategies such as hematopoietic stem cell transplantation.

Feature	Our Test (NGS)	Closest Alternative (Sanger Sequencing)
Methodology	Next‑Generation Sequencing (full gene with CNV analysis)	Sanger sequencing of coding exons (may miss large deletions/duplications)
Diagnostic Sensitivity	99.9% for all mutation types (point mutations, indels, CNVs)	~95% (point mutations/small indels only)
Turnaround Time	3–4 Weeks	4–6 Weeks
Price (AED)	2,800	Often comparable or higher with add‑ons

Physician Insight & Safety Protocols

"As a Consultant Medical Genetics, I emphasize that the identification of a pathogenic variant in the CYBB gene, when correlated with clinical presentation and neutrophil function assays, confirms the diagnosis of X-linked chronic granulomatous disease. This genetic analysis is a cornerstone of precision healthcare for affected families in the UAE. All treatment decisions must be individualized; never stop prescribed prophylactic medications without your physician's direct oversight."

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA License 9294403

Advisory: Medication & Treatment Guidance

Important Advisory: Do not discontinue or alter any prescribed medications, including prophylactic antibiotics or antifungals, without consulting your treating physician. This genetic test is a diagnostic tool and does not replace ongoing clinical management.

Test Safety & Exclusion Criteria

Patient Exclusion and Red Flags

Exclusion: Individuals without clinical suspicion of CGD, a documented family history of the condition, or a prior Genetic Counselling session are not eligible for this test.
Exclusion: Prenatal diagnosis requires a dedicated, multidisciplinary protocol and is not covered by standard home collection services.
ER Red Flags: If you develop sudden fever, respiratory distress, skin abscess, or signs of severe infection, visit the nearest emergency department immediately – do not wait for genetic results.

Patient FAQ & Clinical Guidance

1. What is the CYBB gene NGS test and how does it diagnose X‑linked CGD?

This DNA test uses next‑generation sequencing to read all coding regions and splice sites of the CYBB gene, identifying mutations that cause X‑linked chronic granulomatous disease. It accurately diagnoses affected males and identifies female carriers.

2. How should I prepare for the test and what sample is required?

A prior genetic counselling session with pedigree charting is mandatory. Acceptable samples include whole blood, extracted DNA, or a dried blood spot on an FTA card. Disclose your full medication history and current symptoms before sample collection.

3. What is the turnaround time and how will I receive my results?

Results are typically ready in 3 to 4 weeks and are delivered through a secure online portal. This is accompanied by a mandatory telephonic post-test clinical guidance session to interpret your results and discuss next steps.

UAE Regulatory & Data Privacy Adherence

DNA Labs UAE strictly adheres to the UAE's comprehensive legal framework for health data protection. All genetic test data is processed and stored in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols follow the standards established by Federal Decree-Law No. 4 of 2016 on Medical Liability. Your personal health information is encrypted, access-controlled, and never shared without your explicit consent. This ensures the highest standards of confidentiality and trust in our genetic testing services.

Clinical & Logistical Metadata

Test Name	CYBB Gene Genetic Test for X-Linked Chronic Granulomatous Disease (NGS)
Price (AED)	2,800 AED
Turnaround Time	3 to 4 Weeks
Sample Type / Matrix	Whole Blood (Peripheral Blood) or Extracted DNA; Dried Blood Spot (FTA Card) also accepted. VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
Methodology Used	Next-Generation Sequencing (NGS) with CNV Analysis
ICD-10-CM Code	D82.0 (Chronic granulomatous disease)
LOINC Code	101377-8 (CYBB gene mutation analysis in blood by NGS)
DHA Facility License & Laboratory Address	DNA Labs UAE \| DHA Facility License Number: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE